Scott & Selber, Inc. Gilead Sciences, Inc. Transaction History

Scott & Selber, Inc.

$314 Million
Q2 2024

A detailed history of Scott & Selber, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Scott & Selber, Inc. holds 11,058 shares of GILD stock, worth $935,396. This represents 0.24% of its overall portfolio holdings.

Number of Shares

11,058

Previous 10,977 0.74%

Holding current value

$935,396

Previous $804,000 5.6%

% of portfolio

0.24%

Previous 0.27%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	BUY	$63.15 - $72.88 $5,115 - $5,903	81 Added 0.74%	11,058 $759,000
Q1 2024 May 01, 2024	SELL	$71.58 - $87.29 $5,082 - $6,197	-71 Reduced 0.64%	10,977 $804,000
Q4 2023 Feb 01, 2024	SELL	$73.27 - $83.09 $1,978 - $2,243	-27 Reduced 0.24%	11,048 $895,000
Q3 2023 Oct 24, 2023	SELL	$73.94 - $80.67 $1,626 - $1,774	-22 Reduced 0.2%	11,075 $830,000
Q2 2023 Jul 27, 2023	SELL	$76.01 - $86.7 $2,128 - $2,427	-28 Reduced 0.25%	11,097 $855,000
Q1 2023 Apr 18, 2023	BUY	$77.31 - $88.08 $2,937 - $3,347	38 Added 0.34%	11,125 $923,000
Q4 2022 Jan 31, 2023	SELL	$62.32 - $89.47 $747 - $1,073	-12 Reduced 0.11%	11,087 $952,000
Q3 2022 Oct 21, 2022	BUY	$59.54 - $68.01 $2,857 - $3,264	48 Added 0.43%	11,099 $685,000
Q2 2022 Jul 28, 2022	SELL	$57.72 - $65.01 $42,712 - $48,107	-740 Reduced 6.28%	11,051 $683,000
Q1 2022 May 03, 2022	SELL	$57.92 - $72.58 $9,383 - $11,757	-162 Reduced 1.36%	11,791 $701,000
Q4 2021 Feb 04, 2022	BUY	$64.88 - $73.64 $775,510 - $880,218	11,953 New	11,953 $868,000

Others Institutions Holding GILD

# of Institutions

1,880

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $106B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Scott & Selber, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Scott & Selber, Inc. with notifications on news.

Account